Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2- and PI3K-induced STAT1/3 in HepG2 hepatocyte cells

Abstract

Interleukin-6 (IL-6) is the major activator of the acute phase response (APR). One important regulator of IL-6-activated APR is peroxisome proliferator-activated receptor alpha (PPARα). Currently, there is a growing interest in determining the role of PPARα in regulating APR; however, studies on the molecular mechanisms and signaling pathways implicated in mediating the effects of IL-6 on the expression of PPARα are limited. We previously revealed that IL-6 inhibits PPARα gene expression through CAAT/enhancer-binding protein transcription factors in hepatocytes. In this study, we determined that STAT1/3 was the direct downstream molecules that mediated the Janus kinase 2 (JAK2) and phosphatidylinositol-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathways in IL-6-induced repression of PPARα. Treatment of cells with pharmacological inhibitors of JAK2, PI3K, AKT, and mTOR attenuated the inhibitory effect of IL-6 on PPARα protein in a dose-dependent manner. These inhibitors also decreased the IL-6-induced repression of PPARα mRNA expression and promoter activity. Overexpression of STAT1 and STAT3 in HepG2 cells cotransfected with a reporter vector containing this PPARα promoter region revealed that both the expression plasmids inhibited the IL-6-induced repression of PPARα promoter activity. In the presence of inhibitors of JAK2 and mTOR (AG490 and rapamycin, respectively), IL-6-regulated protein expression and DNA binding of STAT1 and STAT3 were either completely or partially inhibited simultaneously, and the IL-6-induced repression of PPARα protein and mRNA was also inhibited. This study has unraveled novel pathways by which IL-6 inhibits PPARα gene transcription, involving the modulation of JAK2/STAT1-3 and PI3K/AKT/mTOR by inducing the binding of STAT1 and STAT3 to STAT-binding sites on the PPARα promoter. Together, these findings represent a new model of IL-6-induced suppression of PPARα expression by inducing STAT1 and STAT3 phosphorylation and subsequent down-regulation of PPARα mRNA expression.

A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway

“…Several important signaling pathways are in association with STAT3 activation, including MAPK/ERK [ 24 ], PI3K/AKT/mTOR [ 25 ], c-Src [ 26 ], and JAK pathways [ 24 ]. We next evaluated the effects of SC99 on these specific kinases including JAK2, ERK, AKT, mTOR, and c-Src by immunoblotting.…”

CCL27 Is Downregulated by Interferon Gamma via Epidermal Growth Factor Receptor in Normal Human Epidermal Keratinocytes

“…The precise mechanism underlying CTACK/CCL27 suppression via STAT3 is unknown. Although STATs are transcriptional activators, they also appear to act as transcriptional repressors (Zhou and Waxman, ; Chew et al, ). Previous reports indicated that STAT3 acted as a transcriptional repressor to PPARα.…”

A novel STAT3 inhibitor negatively modulates platelet activation and aggregation

“…Several important signaling pathways are associated with STAT3 activation, including MAPK/ERK [18] , PI3K/AKT [19] , c-Src [20] , and JAK pathways [18] . Our previous studies showed that SC09 had no effects on these kinases with the exception of JAK2 in multiple myeloma cells [16] , we next confirmed the effects of SC99 on these kinases in platelets.…”